Persistent iatrogenic bone marrow aplasia after salvage therapy for acute myeloblastic leukemia (AML) is a difficult clinical problem. The policy of close observation and supportive therapy with hematopoietic growth factors while waiting for spontaneous bone marrow recovery has not proved successful. In this setting, non-myeloablative allogeneic stem cell transplantation (NST) may be the only chance for short-term and long-term survival. The appropriate doses, schedule and intensity of the conditioning regimen are still unresolved issues. We report a patient with relapsed AML who was successfully treated with NST using only fludarabine as a chemotherapeutic agent in the conditioning regimen.
In March 2005, a 51-year-old woman presented with pancytopenia. A bone marrow aspirate showed 77% types I and II blast cells positive for CD117, CD33 and CD13. There were no Auer rods. The karyotype was 46,XX, del(3)(p13) in 20/20 metaphases. A diagnosis of AML type M2, according to the French-American-British classification was made, belonging to the intermediate risk group according to Medical Research Council criteria. In May 2003, the patient had been treated for bilateral ductalmammary carcinoma in situ and underwent bilateral mastectomy followed by adjuvant chemotherapy consisting of six cycles of chemotherapy (cyclophosphamide, epirubicin and 5-fluorouracil) and tamoxifen. Genetic testing revealed germline BRCA-1 and BRCA-2 genes, but because of familial occurrence of breast cancer, prophylactic oophorectomy was performed. The patient was treated for leukemia at another institution with induction chemotherapy (daunorubicin and cytosine arabinoside) obtaining complete hematological remission. Afterwards, she received two consolidation cycles, the last one including high-dose cytosine arabinoside. The option of allogeneic stem cell transplantation was discussed with the patient because of the possibility that the leukemia could be secondary to previous chemotherapy, but the deletion of chromosome 3p was judged as nonspecific for secondary leukemia and it was decided that a search for a donor and transplantation be postponed until an eventual leukemia relapse. The patient suffered from relapse in January 2006, with morphological and immuno-phenotypic characteristics of AML identical to those observed previously. Reinduction treatment was administered with amsacrine and cytosine arabinoside and the patient was transferred to our hospital. According to Swedish National Guidelines for AML, a bone marrow aspiration was performed on day þ 15 after start of chemotherapy. The bone marrow was hypocellular with 30% myeloblasts. Because of the resistant nature of the leukemia, therapy with fludarabine, high-dose cytosine arabinoside and idarubicin was commenced in spite of hypoplasia. Bone marrow aspirations on day 15 and day 28 showed no cells, which could be examined. A bone marrow biopsy showed hypocellularity with a few bone marrow cells, which were difficult to characterize. Flow cytometry did not reveal any sign of AML. The morphological picture was identical to severe aplastic anemia. At that moment it was impossible to tell with certainty if the AML stem cell clone was present or not. An unrelated HLA-identical donor was found, and the patient underwent NST after 2 months of continuing aplasia with regular platelet transfusions and leukocyte counts 0-0.1 Â 10 9 /l. The conditioning regimen consisted of daily intravenous fludarabine 25 mg/m 2 from day À3 to day À1, daily antithymocyte globulin (ATG) (Fresenius) 10 mg/ kg from day À5 to day À2. Cyclosporine and methotrexate (8 mg/m 2 , days þ 2, þ 4 and þ 8) were administered for graft-versus-host disease (GVHD) prophylaxis. A total of 6.08 Â 10 6 unmanipulated peripheral CD34 þ cells/kg were infused. Neutrophil and platelet engraftment occurred day þ 24 and day þ 28. The course of recovery was complicated by bacterial infection of the breast prostheses, which were surgically removed. The infection subsided rapidly. Bone marrow aspiration was normocellular on day þ 40 and showed complete hematological remission. Chimerism analysis showed 16% donor cells on day þ 30, and on day 50 they represented only 6% of the cells. The patient was discharged day þ 42 after transplantation. The course was uneventful until 3 months after transplantation when relapse occurred. The patient is currently at home 6 months after transplantation and in complete remission again after chemotherapy and donor lymphocyte infusions (DLI). There has been no sign of acute or chronic GVHD. This patient had refractory AML which appeared 2 years after successful treatment for breast cancer. The risk of secondary myelodysplastic syndromes and AML after adjuvant chemotherapy for breast cancer is thought to correlate with the doses of epirubicin and cyclophosphamide. 1 We could not determine with certainty if the leukemia was secondary to previous treatment. The impact of the disease status on long-term outcome after allogeneic transplantation has been investigated by many single centers and cooperative studies, usually by comparing the outcome of patients transplanted in complete remission with that of patients transplanted in relapse. The significance of disease burden in 161 AML patients receiving bone marrow transplants from unrelated donors between 1985 and 1998 has been evaluated recently. Leukemia-free survival at 5 years was 50712% for patients transplanted in first remission, compared to 27717% for patients transplanted in second or subsequent remission, and 773% for patients transplanted in relapse. Among patients transplanted in relapse, those with o30% leukemic blasts in the marrow and no circulating blasts had 37% risk of relapse after stem cell transplantation, those with 430% blasts in the marrow and no circulating blasts had a risk of 44% and those with both leukemic blasts in the marrow and circulating leukemic blasts had a relapse risk of 50%. 2, 3 We have been unable to find any reports or specific data on the outcome for patients with persistent iatrogenic bone marrow aplasia after chemotherapy. We assume that in the present case the burden of disease as well as the number of normal stem cells were significantly reduced with standard chemotherapy and the decision to do the transplantation was justified even if we could not be certain if the patient would regenerate with blast cells or achieve a complete remission. Reduced-intensity conditioning regimens including fludarabine have been successfully applied in the setting of allogeneic stem cell transplantation for refractory acute myeloid leukemia. 4 To our knowledge, fludarabine has always been combined with other drugs such as cyclophosphamide, amsacrine, busulfan or total body irradiation in the conditioning regimen. However, the questions of optimal drug selection, their combination and doses are not answered. The only patient in the study of Schmid et al. 4 with true aplasia who received two prophylactic DLI, suffered GVHD grade III which was well controlled with steroids and is now in complete remission 5 years after NST (C Schmid, personal communication). The role of prophylactic DLI incorporated in the setting of NST for advanced hematological malignancy in selected groups of patients could be of interest for future strategies. 5 In conclusion, this intriguing case shows that fludarabine alone without the addition of other cytotoxic drugs could be used with ATG in the setting of unrelated stem cell transplantation as a salvage therapy for conditioning in severe iatrogenic aplasia. Although the follow-up is only 6 months after transplantation, we have shown that our approach of using genuinely reduced conditioning that we colloquially called 'micro' allogeneic stem cell transplantation can be feasible.
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